Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 8/20 | 0.47 |
| ▸ | TOP2B | Q02880 | 8/20 | 0.47 |
| ▸ | DPP4 | P27487 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ATP6V1B2 | P21281 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | EDNRA | P25101 | 1/20 | 0.42 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9097293 | 0.86 | DPP4 (0.47) | TOP2ATOP2BDPP4LMNACYP2C9 | |
| SCHEMBL501153 | 0.86 | DPP4 (0.47) | TOP2ATOP2BDPP4LMNACYP2C9 | |
| SCHEMBL9014149 | 0.86 | DPP4 (0.47) | TOP2ATOP2BDPP4LMNACYP2C9 | |
| SCHEMBL10330767 | 0.86 | TOP2A (0.59) | TOP2ATOP2BDPP4LMNACYP2C9 | |
| SCHEMBL9283675 | 0.81 | DPP4 (0.44) | TOP2ATOP2BDPP4LMNACYP2C9 | |
| SCHEMBL7014272 | 0.80 | TOP2A (0.41) | TOP2ATOP2BDPP4CHRM2DRD1 | |
| SCHEMBL13483625 | 0.79 | DPP4 (0.51) | TOP2ATOP2BDPP4LMNACYP2C9 | |
| SCHEMBL5653361 | 0.79 | KDM4E (0.44) | TOP2ATOP2BDPP4LMNACYP2C9 | |
| SCHEMBL5653364 | 0.79 | KDM4E (0.44) | TOP2ATOP2BDPP4LMNACYP2C9 | |
| SCHEMBL10330768 | 0.79 | KDM4E (0.48) | TOP2ATOP2BLMNACYP2C9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-22 | — | — | US | disclosed |
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-22 | — | — | US | disclosed |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2013-01-31 | — | — | US | disclosed |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2013-01-31 | — | — | US | disclosed |
| US-8222407-B2 | Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-07-17 | — | — | US | disclosed |
| US-8222407-B2 | Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2012-05-03 | — | — | US | disclosed |
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2012-05-03 | — | — | US | disclosed |
| US-20100197909-A1 | MUTILIN DERIVATIVE HAVING HETEROCYCLIC AROMATIC RING CARBOXYLIC ACID STRUCTURE IN SUBTITUENT AT 14-POSITION | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197909-A1 | MUTILIN DERIVATIVE HAVING HETEROCYCLIC AROMATIC RING CARBOXYLIC ACID STRUCTURE IN SUBTITUENT AT 14-POSITION | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-7186843-B2 | potent antibacterial activity against various bacteria including drug-resistant strains | DAIICHI PHARMACEUTICAL CO. LTD. (JP) | 2007-03-06 | — | — | US | disclosed |
| US-7186843-B2 | potent antibacterial activity against various bacteria including drug-resistant strains | DAIICHI PHARMACEUTICAL CO. LTD. (JP) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | NQO2, QDPR, IL4I1 | TOP2A 89/4885TOP2B 149/4885DPP4 2696/4885 |
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | NQO2, QDPR, IL4I1 | TOP2A 89/4885TOP2B 149/4885DPP4 2696/4885 |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | NQO2, QDPR, IL4I1 | TOP2A 89/4885TOP2B 149/4885DPP4 2696/4885 |
| US-20100197909-A1 | MUTILIN DERIVATIVE HAVING HETEROCYCLIC AROMATIC RING CARBOXYLIC ACID STRUCTURE IN SUBTITUENT AT 14-POSITION | PELP1, MLN, SND1 | TOP2A 3897/4885TOP2B 4117/4885DPP4 1189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.